Veracyte (VCYT)
(Delayed Data from NSDQ)
$21.67 USD
-0.32 (-1.46%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $21.67 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth A Momentum D VGM
Veracyte (VCYT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$29.83 | $37.00 | $21.00 | 35.65% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Veracyte comes to $29.83. The forecasts range from a low of $21.00 to a high of $37.00. The average price target represents an increase of 35.65% from the last closing price of $21.99.
Analyst Price Targets (6 )
Broker Rating
Veracyte currently has an average brokerage recommendation (ABR) of 1.92 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.92 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 55.56% and 11.11% of all recommendations. A month ago, Strong Buy made up 55.56%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/VCYT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.92 | 1.92 | 1.92 | 1.92 | 1.92 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/16/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
5/8/2024 | Raymond James | Andrew Cooper | Hold | Hold |
5/8/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
4/15/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
2/23/2024 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
12/15/2023 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
11/7/2023 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.92 |
ABR (Last week) | 1.92 |
# of Recs in ABR | 9 |
Average Target Price | $29.83 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 162 of 252 |
Current Quarter EPS Est: | -0.03 |